Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683030 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
A Phase 3 study, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 3
- Development phase
- 397
- Enrollment target
NCT03683030 is a Phase 3 study that has completed, run by Biosense Webster. The registered enrollment target is 397 participants.
The verdict
NCT03683030, a Phase 3 study, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 397 participants
- Enrollment target
Study Summary
The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.
Interventions
- DEVICE Multi-Electrode RF Balloon Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03683030
The ClinicalTrials.gov registry entry for NCT03683030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multi-Electrode RF Balloon Catheter is the first listed.
NCT03683030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03683030 about?
NCT03683030 is a clinical study titled "Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation". The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.
What is the current status of trial NCT03683030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 397 participants. The study started on 2018-10-22. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT03683030?
The interventions under investigation include: Multi-Electrode RF Balloon Catheter (DEVICE).
Who is sponsoring clinical trial NCT03683030?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.